prikaz prve stranice dokumenta Does the Efficacy of Semaglutide Treatment Differ between Low-Risk and High-Risk Subgroups of Patients with Type 2 Diabetes and Obesity Based on SCORE2, SCORE2-Diabetes, and ASCVD Calculations?
  Download
PDF 3.15 MB
Scientific paper - Original scientific paper
Does the Efficacy of Semaglutide Treatment Differ between Low-Risk and High-Risk Subgroups of Patients with Type 2 Diabetes and Obesity Based on SCORE2, SCORE2-Diabetes, and ASCVD Calculations?
Diabetology, 5 (2024), 1; 26-39. https://doi.org/10.3390/diabetology5010003
Matovinović, Martina; Belančić, Andrej; Jug, Juraj; Mustač, Filip; Sirovica, Maja; Santini, Mihovil; Bošnjaković, Anja; Lovrić, Mario; Lovrić Benčić, Martina

Cite this document

Matovinović, M., Belančić, A., Jug, J., Mustač, F., Sirovica, M., Santini, M. ... Lovrić Benčić, M. (2024). Does the Efficacy of Semaglutide Treatment Differ between Low-Risk and High-Risk Subgroups of Patients with Type 2 Diabetes and Obesity Based on SCORE2, SCORE2-Diabetes, and ASCVD Calculations?. Diabetology, 5. (1), 26-39. doi: 10.3390/diabetology5010003

Matovinović, Martina, et al. "Does the Efficacy of Semaglutide Treatment Differ between Low-Risk and High-Risk Subgroups of Patients with Type 2 Diabetes and Obesity Based on SCORE2, SCORE2-Diabetes, and ASCVD Calculations?." Diabetology, vol. 5, no. 1, 2024, pp. 26-39. https://doi.org/10.3390/diabetology5010003

Matovinović, Martina, Andrej Belančić, Juraj Jug, Filip Mustač, Maja Sirovica, Mihovil Santini, Anja Bošnjaković, Mario Lovrić and Martina Lovrić Benčić. "Does the Efficacy of Semaglutide Treatment Differ between Low-Risk and High-Risk Subgroups of Patients with Type 2 Diabetes and Obesity Based on SCORE2, SCORE2-Diabetes, and ASCVD Calculations?." Diabetology 5, no. 1 (2024): 26-39. https://doi.org/10.3390/diabetology5010003

Matovinović, M., et al. (2024) 'Does the Efficacy of Semaglutide Treatment Differ between Low-Risk and High-Risk Subgroups of Patients with Type 2 Diabetes and Obesity Based on SCORE2, SCORE2-Diabetes, and ASCVD Calculations?', Diabetology, 5(1), pp. 26-39. doi: 10.3390/diabetology5010003

Matovinović M, Belančić A, Jug J, Mustač F, Sirovica M, Santini M, and sur.. Does the Efficacy of Semaglutide Treatment Differ between Low-Risk and High-Risk Subgroups of Patients with Type 2 Diabetes and Obesity Based on SCORE2, SCORE2-Diabetes, and ASCVD Calculations?. Diabetology [Internet]. 2024 January 04 [cited 2024 May 27];5(1):26-39. doi: 10.3390/diabetology5010003

M. Matovinović, et al., "Does the Efficacy of Semaglutide Treatment Differ between Low-Risk and High-Risk Subgroups of Patients with Type 2 Diabetes and Obesity Based on SCORE2, SCORE2-Diabetes, and ASCVD Calculations?", Diabetology, vol. 5, no. 1, pp. 26-39, January 2024. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:769094. [Accessed: 27 May 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)Does the Efficacy of Semaglutide Treatment Differ between Low-Risk and High-Risk Subgroups of Patients with Type 2 Diabetes and Obesity Based on SCORE2, SCORE2-Diabetes, and ASCVD Calculations?
AuthorMartina Matovinović
AuthorAndrej Belančić
AuthorJuraj Jug
AuthorFilip Mustač
AuthorMaja Sirovica
AuthorMihovil Santini
AuthorAnja Bošnjaković
AuthorMario Lovrić
AuthorMartina Lovrić Benčić
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Pharmacology)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Abstract (english)
Background: Diabetes is the primary contributor to cardiovascular disease risk, and when combined with obesity, it further underscores the significance of cardiovascular risk assessment. Methods: A retrospective study of 64 patients with type 2 diabetes (T2D) and obesity on once-weekly subcutaneous semaglutide stratified by cardiovascular risk categories determined using the SCORE2/SCORE2-OP, SCORE2-Diabetes, and ASCVD score calculations. We compare the differences between groups (ASCVD: low + borderline + intermediate versus high-risk group; SCORE2/SCORE2-OP: low + moderate versus high + very high-risk group and SCORE2-Diabetes: low + moderate versus high + very high-risk group) in terms of change from baseline in body mass index (BMI) and HbA1c and weight loss outcomes. Results: Patients in the high-risk group, according to ASCVD risk score, had statistically better results in weight loss ≥ 3%, ≥5%, and ≥10% compared to ASCVD low + borderline + intermediate and without difference regarding HbA1c. According to SCORE2/SCORE2-OP, the high + very high-risk group had statistically better HbA1c and weight loss results but only for ≥5% versus the low + moderate risk group. Based on the score SCORE2-Diabetes, the high + very high-risk group had statistically significant better results in lowering HbA1c and weight loss but only for ≥5% versus the low + moderate risk group. Conclusions: To the best of our knowledge, this study represents the initial investigation linking glycemic control and weight reduction outcomes in individuals with T2D and obesity treated with once-weekly semaglutide stratified by cardiovascular risk categories determined using the SCORE2/SCORE2-OP, SCORE2-Diabetes and ASCVD score calculations.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review - international
Publication versionPublished version
Journal titleDiabetology
Numberingvol. 5, no. 1, pp. 26-39
e-ISSN2673-4540
DOIhttps://doi.org/10.3390/diabetology5010003
URN:NBNurn:nbn:hr:184:769094
Publication2024-01-04
Document URLhttps://www.mdpi.com/2673-4540/5/1/3
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution 4.0 International (CC BY 4.0) icon
Created on2024-01-05 12:24:56